The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.
Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-gamma is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-gamma plays a role in both adipocyte differentiation and carcinogenesis. PPAR-gamma is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-gamma in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-gamma ligand.
Matsuyama
Masahide
M
Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Yoshimura
Rikio
R
Clin Cancer Res. 2005 Mar 1;11(5):1999-2007
15756026
Biochem Biophys Res Commun. 2004 Mar 12;315(3):624-35
14975747
Cancer. 2000 Aug 1;89(3):589-96
10931458
Cell Growth Differ. 2000 Jan;11(1):49-61
10672903
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1710-6
15533897
Neoplasia. 2004 Nov-Dec;6(6):821-30
15720809
J Clin Invest. 2000 Jul;106(2):189-97
10903334
Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14
17447067
Cancer Lett. 2003 Feb 28;191(1):67-74
12609711
Am J Physiol. 1991 Feb;260(2 Pt 1):L13-28
1899973
Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692-6
1849272
Prostate. 2000 Jan;42(1):73-8
10579801
Biochem Biophys Res Commun. 2003 Jul 25;307(2):342-9
12859962
Cancer Sci. 2007 Sep;98(9):1417-23
17645780
Nature. 1996 Nov 7;384(6604):39-43
8900274
J Med Chem. 2004 Dec 2;47(25):6195-206
15566290
PPAR Res. 2008;2008:249849
18317513
Biochem Biophys Res Commun. 2001 Sep 28;287(3):727-32
11563856
Anticancer Res. 2007 Jul-Aug;27(4B):2393-402
17695530
J Urol. 1998 Oct;160(4):1220-9
9751323
Cancer Res. 1995 Sep 1;55(17):3785-9
7641194
Prostate. 2002 May 1;51(2):108-16
11948965
Int J Mol Med. 2004 Jun;13(6):789-93
15138613
J Urol. 2003 Nov;170(5):1994-9
14532840
Oncol Rep. 2007 Jul;18(1):99-104
17549353
Biochim Biophys Acta. 1996 Nov 11;1304(1):65-84
8944751
Endocrinology. 1996 Jan;137(1):354-66
8536636
Biochem Biophys Res Commun. 2000 Apr 13;270(2):400-5
10753637
Int J Mol Med. 2004 May;13(5):665-8
15067367
BMC Cancer. 2006 Mar 06;6:53
16519808
Urology. 2000 Oct 1;56(4):671-6
11018637
J Urol. 2000 Sep;164(3 Pt 1):820-5
10953162
J Biol Chem. 1997 Mar 21;272(12):8071-6
9065481
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182-7
9789062
Nature. 1990 Oct 18;347(6294):645-50
2129546
J Biol Chem. 2000 Apr 14;275(15):11397-403
10753955
Clin Cancer Res. 2003 Aug 15;9(9):3503-13
12960143
Prostate. 2006 Feb 15;66(3):257-65
16175586
Int J Oncol. 2004 Apr;24(4):821-7
15010818